Heartflow, Inc.

Heartflow, Inc. develops software-based cardiovascular diagnostics that analyze coronary CT angiography (CCTA) images to help physicians assess coronary artery disease without invasive procedures. Its commercial platform is sold on a usage-driven basis, with core products including Heartflow FFRCT Analysis and Heartflow Plaque Analysis, and it is expanding into workflow tools such as Heartflow RoadMap and the planned PCI Planner.

−33,3 %

76,8 %

−66,3 %

+39,9 %

5.20

5.20

— Heartflow, Inc.
%
FFRCT Analysis98% AI-enabled coronary physiology analysis used to assess blood flow restriction from CCTA scans.
Plaque Analysis2% Coronary plaque assessment product used to support treatment decisions and risk stratification.
Workflow tools0% RoadMap and planned PCI Planner features that improve workflow efficiency and retention.

Heartflow sells primarily to hospitals, health systems, and imaging centers that order analyses for patients being...

  • Large health systemsprimary

    Multi-facility systems that buy access across several accounts and drive meaningful case volume.

  • Individual hospital and imaging accountsprimary

    Facilities that order FFRCT and plaque analyses for routine CAD evaluation.

  • Referring physicianssecondary

    Cardiologists and other clinicians who choose Heartflow to avoid invasive testing and improve triage.

  • Payors and reimbursement decision-makersprimary

    Government and third-party payors whose coverage and payment policies determine adoption economics.

Heartflow’s commercial base is centered in the United States, where it had more than 1,100 accounts as of December 31,...

  • •United States is the core market and main source of installed-base growth
  • •International presence includes the UK, EU, Australia, Canada, and Japan
  • •Small direct commercial teams support non-U.S. markets
  • •No manufacturing footprint was disclosed; business is software and service based
  • •Coverage and reimbursement vary by country and affect adoption speed

Heartflow is focused on expanding utilization within its installed base while adding new accounts through a scalable,...

01
Grow utilization at existing accountsshort-term

Revenue is usage-driven, so more cases per account directly increase sales.

02
Expand Plaque Analysis adoptionmedium-term

The product is a long-term growth driver but still early in commercialization.

03
Build a broader platform around workflow and PCI planningmedium-term

Adjacent tools can improve retention and make the platform more embedded in care pathways.

04
Scale international commercializationlong-term

Approved markets outside the U.S. provide additional growth without changing the core product.

Heartflow is highly exposed to reimbursement policy, physician adoption, and customer concentration because most...

high

Dependence on a single core product

Substantially all revenue is generated by Heartflow FFRCT Analysis, making results sensitive to one offering.

Scope
FFRCT Analysis
Materiality
high
high

Reimbursement and coverage risk

If payors do not cover the platform or reduce payment amounts, provider adoption can slow materially.

Scope
Government and third-party payors
Materiality
high
high

AI and model performance risk

Incorrect design, poor data, bugs, or cybersecurity issues could impair product performance and create liability.

Scope
AI algorithms and computational fluid dynamics models
Materiality
high
medium

Customer concentration

A small number of large health systems can represent a disproportionate share of revenue.

Scope
Large health systems and multi-account customers
Materiality
medium
medium

Plaque Analysis commercialization risk

The product is still nascent and may not achieve expected market acceptance or utilization.

Scope
New product adoption
Materiality
medium
Usage-based revenue recognition
Can create volatility in reported revenue and margins
Seasonality and utilization variability
Makes quarter-to-quarter comparisons less comparable
Capitalized software and contract fulfillment costs
Affects gross margin and operating leverage
Stock-based compensation
Impacts operating loss and non-cash expense profile
Debt conversion and repayment around IPO
Affects interest expense, leverage, and cash flow presentation

HeartSciences Inc.

HSCS · Finance Services

HeartBeam, Inc.

BEAT · Surgical & Medical Instruments & Apparatus

Hyperfine, Inc.

HYPR · Electromedical & Electrotherapeutic Apparatus

HeartCore Enterprises, Inc.

HTCR · Services-Computer Processing & Data Preparation

BIOTRICITY INC.

BTCY · Surgical & Medical Instruments & Apparatus

iRhythm Holdings, Inc.

IRTC · Surgical & Medical Instruments & Apparatus

: 28/04/2026